Net income for the first quarter of 2026 was $45.3 million, compared to $26.9 million in the same period of 2025. Total revenues were $114.5 million, relatively flat compared to $114.8 million in Q1 2025. ASCENIV sales grew 27.7% to $97.5 million, offsetting a 54% decline in BIVIGAM sales to $15.4 million. Gross profit margin improved significantly to 70.5% from 53.2% in Q1 2025, attributed to the new yield enhancement process. Operating income rose to $58.3 million from $34.9 million in the prior year period. The company completed the sale of three plasma collection centers, resulting in a gain of $8.0 million.